title: Pertussis: acellular, whole-cell, new vaccines, what to choose?
authors.affiliation: a Univ. Lille, U1019 - UMR 8204 - CIIL , Centre for Infection and Immunity of Lille , Lille , France.|b CNRS , UMR 8204, Lille , France.|c Inserm , U1019, Lille , France.|d CHU Lille , Lille , France.|e Institut Pasteur de Lille , Lille , France.
authors.forename: Camille
authors.initials: C
authors.lastname: Locht
mesh_terms: D001886:Bordetella pertussis / Q000276:immunology*; D000066491:Clinical Decision-Making; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014611:Vaccination; D014917:Whooping Cough / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission
chemical_list: D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D010567:Pertussis Vaccine
keywords: Pertussis; acellular vaccines; live vaccines; maternal vaccination; whole-cell vaccines